Should one really ponder those three "ifs" you give they would see that the odds for success are surprisingly very, very high IMO.
RBL and Military Presentations - If they were not to discuss superlative results why would they even be giving them? No need to waste everyone's time by talking about losers.
Phase II CV19 Human Trial - We know we have the science for B to work and it has shown a remarkable ability to transfer in vivo testing results into actual clinical trial results (so much for the efficacy part) and it's safety profile has been established by prior trials and also by the expansion in this trial of dosing from 3 days to 5 days.
I believe the human trial results will be explosive for CV19, the Virology Conference will be good but not necessarily over the top great for B as an antiviral since I don't know how broad the RBLs testing has progressed to date, but the Military presentation will blow the lid sky high on showing the broad spectrum abilities of Brilacidin.
By late August Brilacidin will be a mainstay in the daily worldwide coverage of top drugs expected to set the world on it's ear.
News 
Market Data 
Discover 
